

REDUCE

Current price:	A\$4.17
Target price:	A\$2.16
Previous target:	A\$1.71
Up/downside:	-48.2%
Reuters:	PAR.AX
Bloomberg:	PAR AU
Market cap:	US\$553.9m
	A\$824.9m
Average daily turnover:	US\$2.81m
	A\$4.12m
Current shares o/s	192.2m
Free float:	72.2%



Price performance	1M	ЗM	12M
Absolute (%)	23	39.9	268.
Relative (%)	20.6	34	250.

Iain WILKIE

T (61) 7 3334 4521

E iain.wilkie@morgans.com.au

Scott POWER

T (61) 7 3334 4884

E scott.power@morgans.com.au

Dr Derek JELLINEK

T (61) 2 9043 7904

E derek.jellinek@morgans.com.au

Analyst(s) own shares in the following stock(s) mentioned in this report:

- N/A

Paradigm Biopharmaceuticals

Cautious view remains

- PAR reported its 1H20 result with expenses largely in line with expectations. No further detail or commentary was provided in the report.
- We maintain our cautious view on the stock with current valuation pricing in significantly higher expectations of potential licensing deal value and market share assumptions than we see as reasonable.
- We have rolled forward our model and made minor changes to our assumptions. Our price target increases to A\$2.16 (from A\$1.71) although we retain a Reduce recommendation. We note an investment in PAR is appropriate for investors with a higher risk profile.

1H20 results

PAR posted a 1H20 net loss of A\$5.1m for the period (~14% increase in the pcp). Expense items grew in line with expectations with a 35% increase in R&D and employee expenses, and a 25% increase in general and administration costs. Cash balance remains strong with A\$70.1m in cash after the A\$77.9m capital raise in late FY19 and a further A\$1.4m via the exercising of options in the 1H20 period.

Better risk-adjusted plays in the space

We remain wary after PAR's change in strategy mid last year and what we view as interesting but inconclusive results on its Ph2b osteoarthritis (OA) trial, while follow-up studies similarly unconvincing and lack substantive clinical evidence. We view the OA data as an interesting trend but will likely require a more stringent trial design and analysis to flush out critical design parameters for a Ph3 trial and draw out a realistic commercial opportunity. Even taking into consideration our question marks over the trial quality, we still think there is value in the asset, just not at current valuations. The data shown to date, while interesting and showing positive initial trends of efficacy is by no means conclusive and given the significant risks ahead trials / approvals / costs / marketing / time-value, we continue to view PAR as a funding source for better risk-adjusted plays in the space.

Changes to forecasts

We have rolled forward our model and made minor changes including re-weighting partnership and milestone assumptions based on updated biotechnology deal metrics which continue to shift toward higher back-end loaded milestone payments over the last 12 months.

Investment view – retain Reduce recommendation

As a result of the changes to forecasts and rolling forward of our model, our DCF valuation and price target increases to A\$2.16 (from A\$1.71) although we maintain our Reduce recommendation with recent share price rally running well ahead of fundamental value and pricing in significantly higher deal values than what we are seeing across the market, in our view. We continue to advocate investors take profits but maintain a core holding if risk-profile allows. We note this investment is appropriate for investors with higher riskprofiles.

Financial Summary	Jun-18A	Jun-19A	Jun-20F	Jun-21F	Jun-22F
Revenue (A\$m)	2.74	2.98	2.25	4.28	70.20
Operating EBITDA (A\$m)	-6.19	-15.89	-17.10	-50.40	15.17
Net Profit (A\$m)	-6.15	-15.63	-15.50	-49.21	10.82
Normalised EPS (A\$)	-0.04	-0.09	-0.08	-0.25	0.05
Normalised EPS Growth	22681%	115%	(15%)	213%	
FD Normalised P/E (x)	NA	NA	NA	NA	76.26
DPS (A\$)	-	-	-	-	-
Dividend Yield	0%	0%	0%	0%	0%
EV/EBITDA (x)	NA	NA	NA	NA	53.44
P/FCFE (x)	NA	NA	NA	NA	44,514
Net Gearing	(18.0%)	(87.4%)	(88.8%)	(78.0%)	(48.9%)
P/BV (x)	43.52	9.68	12.26	45.59	28.53
ROE	(46%)	(32%)	(21%)	(115%)	46%
% Change In Normalised EPS Estimates					
Normalised EPS/consensus EPS (x)			1.85	1.78	-0.38


SOURCE: MORGANS, COMPANY REPORTS

Amorgans

Paradigm Biopharmaceutica	als		as at February 17, 2020
Market cap (A\$m):	824.9	Rating:	REDUCE
Shares outstanding (m):	192.2	Price (A\$):	4.17
Free float (%):	72.2	Target price (A\$):	2.16
Website:	https://paradigmbiopharma.com/	Upside/downside to target price (%):	-48.2

Company description

Paradigm Biopharmaceuticals Limited (PAR) is an Australian biopharmaceutical company focused on repurposing the drug 'pentosan polysulphate sodium' (PPS) for the treatment of bone marrow edema. Paradigm is targeting addressable markets with the aim to use the shortened development pathway utilising repurposed drugs.



2

Amorgans

Figure 1: Financial summary

Income statement	2018A	2019A	2020F	Year 2021F	2022F	Closing price (A\$)	4.17	Price	e target (A	(\$)	2.16
Divisional sales	0.0	0.0	0.0	0.0	0.0	Valuation metrics		11100	-target (A	Ψ/	2.10
Total revenue	0.0	0.0	0.0	0.0	0.0	Methodology -DCF-PER Comp			Та	rget Price	\$2.16
EBITDA	-6.2	-15.9	-17.1	-50.4	15.2	DCF valuation inputs			14	iget i nee	ψ2.10
Associate income	0.0	0.0	0.0	0.0	0.0	Rf	3.50%		10	-year rate	5.25%
Depreciation	0.0	0.0	0.0	0.0	0.0	Rm-Rf	5.50%		10	Margin	2.0%
EBITA	-6.2	-15.9	-17.1	-50.4	15.2	Beta	1.70			Kd	5.00%
Amortisation/impairment	0.0	0.0	0.0	0.0	0.0	CAPM (Rf+Beta(Rm-Rf))	12.9%			Ke	14.9%
EBIT	-6.2	-15.9	-17.1	-50.4	15.2	E/EV*Ke+D/EV*Kd(1-t)	12.370	N	IPV cash fl		470.9
EBIT(incl associate profit)	-6.2	-15.9	-17.1	-50.4	15.2	Equity (E/EV)	96.2%		nority inter		0.0
Net interest expense/FX	0.0	0.0	0.3	-30.4	1.2	Debt (D/EV)	3.9%	IVII		ebt (A\$m)	0.0
Pre-tax profit		-15.6		-49.2	15.5						
Income tax expense	-6.3		-15.5 0.0	0.0		Interest rate Tax rate (t)	5.00% 30.0%	E au vitu		nts (A\$m)	0.0 470.9
After-tax profit	0.0	0.0 -15.6			4.6	WACC			market va		
	-6.3		-15.5	-49.2		WACC	12.9%	Dilut		. ,	197.8
Minority interests	0.0	0.0	0.0	0.0	0.0				DCF	valuation	\$2.38
NPAT	-6.3	-15.6	-15.5	-49.2	10.8		00404	00404	00005	0004 5	00005
Significant items	0.0	0.0	0.0	0.0	0.0	Multiples	2018A	2019A	2020F	2021F	2022F
NPAT post abnormals	-6.3	-15.6	-15.5	-49.2	10.8	Enterprise value (A\$m)	822.4	752.5	765.1	810.8	810.7
On the film of the second second	00404	00404	00005	00045	0000	EV/Sales (x)	n.a.	n.a.	n.a.	n.a.	n.a.
Cash flow statement	2018A	2019A	2020F	2021F	2022F		-132.9	-47.4	-44.7	-16.1	53.4
EBITDA	-6.2	-15.9	-17.1	-50.4	15.2	EV/EBIT (x)	-132.8	-47.4	-44.7	-16.1	53.4
Other cash items	0.0	0.0	0.0	0.0	0.0	PE (pre-goodwill) (x)	-95.9	-51.3	-53.2	-16.8	76.3
Net interest (pd)/rec	-0.1	-0.3	-1.6	-1.2	-0.3	PEG (pre-goodwill) (x)	-0.2	0.0	0.3	-21.1	-0.4
Taxes paid	0.0	0.0	0.0	0.0	-4.6						
Change in working capital	0.1	9.8	3.0	3.5	-10.8	At target price	2018A	2019A	2020F	2021F	2022F
Cash flow from ops (1)	-6.1	-6.4	-15.7	-48.1	-0.5	EV/EBITDA (x)	-132.8	-47.4	-44.7	-16.1	53.4
Capex (2)	0.0	0.0	0.0	0.0	0.0	PE (pre-goodwill) (x)	-49.7	-26.6	-27.5	-8.7	39.5
Disposals/(acquisitions)	0.0	0.0	0.0	0.0	0.0						
Other investing cash flow	0.0	-6.5	0.0	0.0	0.0	Per share data	2018A	2019A	2020F	2021F	2022F
Cash flow from invest (3)	0.0	-6.5	0.0	0.0	0.0	No. shares	141.5	192.2	197.8	197.8	197.8
Incr/(decr) in equity	5.9	82.8	0.0	0.0	0.0	EPS (cps)	-4.3	-8.1	-7.8	-24.9	5.5
Incr/(decr) in debt	0.0	0.0	0.0	0.0	0.0	EPS (normalised) (c)	-4.3	-8.1	-7.8	-24.9	5.5
Ordinary dividend paid	0.0	0.0	0.0	0.0	0.0	Dividend per share (c)	0.0	0.0	0.0	0.0	0.0
Preferred dividends (4)	0.0	0.0	0.0	0.0	0.0	Dividend payout ratio (%)	0.0%	0.0%	0.0%	0.0%	0.0%
Other financing cash flow	0.0	0.0	0.0	0.0	0.0	Dividend yield (%)	0.0%	0.0%	0.0%	0.0%	0.0%
Cash flow from fin (5)	5.9	82.8	0.0	0.0	0.0						
Forex and disc ops (6)	0.0	0.0	0.0	0.0	0.0	Growth ratios	2018A	2019A	2020F	2021F	2022F
Inc/(decr) cash (1+3+5+6)	-0.3	69.9	-15.7	-48.1	-0.5	Sales growth	n.a.	n.a.	n.a.	n.a.	n.a.
Equity FCF (1+2+4)	-6.2	-6.4	-15.7	-48.1	-0.5	Operating cost growth	n.a.	156.7%	7.6%	194.7%	-130.1%
						EBITDA growth	n.a.	-156.6%	-7.6%	-194.7%	130.1%
Balance sheet	2018A	2019A	2020F	2021F	2022F	EBITA growth	n.a.	n.a.	n.a.	n.a.	n.a.
Cash & deposits	2.4	72.3	59.8	14.1	14.1	EBIT growth	n.a.	n.a.	n.a.	n.a.	n.a.
Trade debtors	2.7	3.5	0.4	0.7	11.5	NPAT growth	n.a.	n.a.	n.a.	n.a.	n.a.
Inventory	0.0	0.0	0.0	0.0	0.0	Pre-goodwill NPAT growth	n.a.	n.a.	n.a.	n.a.	n.a.
Inventory Investments			0.0 0.0	0.0	0.0	Pre-goodwill NPAT growth Pre-goodwill EPS growth	n.a. n.a.	n.a. n.a.	n.a. n.a.	n.a. n.a.	n.a. n.a.
	0.0	0.0				8					
Investments	0.0 0.0	0.0 0.0	0.0	0.0	0.0	Pre-goodwill EPS growth	n.a.	n.a.	n.a.	n.a.	n.a.
Investments Goodwill Other intangible assets	0.0 0.0 0.0 9.9	0.0 0.0 0.0 3.0	0.0 0.0	0.0 0.0	0.0 0.0	Pre-goodwill EPS growth Normalised EPS growth	n.a.	n.a.	n.a.	n.a.	n.a.
Investments Goodwill	0.0 0.0 0.0	0.0 0.0 0.0	0.0 0.0 3.0	0.0 0.0 3.0	0.0 0.0 3.0	Pre-goodwill EPS growth	n.a. n.a.	n.a. n.a.	n.a. n.a.	n.a. n.a.	n.a. n.a.
Investments Goodwill Other intangible assets Fixed assets	0.0 0.0 9.9 0.0	0.0 0.0 0.0 3.0 0.0	0.0 0.0 3.0 0.0	0.0 0.0 3.0 0.0	0.0 0.0 3.0 0.0	Pre-goodwill EPS growth Normalised EPS growth Operating performance Asset turnover (%)	n.a. n.a. 2018A	n.a. n.a. 2019A	n.a. n.a. 2020F	n.a. n.a. 2021F	n.a. n.a. 2022F
Investments Goodwill Other intangible assets Fixed assets Other assets Total assets	0.0 0.0 9.9 0.0 0.0 15.2	0.0 0.0 3.0 0.0 0.0 85.5	0.0 0.0 3.0 0.0 0.0 69.8	0.0 0.0 3.0 0.0 0.0 24.5	0.0 0.0 3.0 0.0 0.0 35.3	Pre-goodwill EPS growth Normalised EPS growth Operating performance Asset turnover (%) EBITDA margin (%)	n.a. n.a. 2018A 0.0 n.a.	n.a. n.a. 2019A 0.0 n.a.	n.a. n.a. 2020F 0.0 n.a.	n.a. n.a. 2021F 0.0 n.a.	n.a. n.a. 2022F 0.0 n.a.
Investments Goodwill Other intangible assets Fixed assets Other assets Total assets Short-term borrowings	0.0 0.0 9.9 0.0 0.0 15.2 0.0	0.0 0.0 3.0 0.0 0.0 85.5 0.0	0.0 0.0 3.0 0.0 0.0 69.8 0.0	0.0 0.0 3.0 0.0 0.0 24.5 0.0	0.0 0.0 3.0 0.0 0.0 35.3 0.0	Pre-goodwill EPS growth Normalised EPS growth Operating performance Asset turnover (%) EBITDA margin (%) EBIT margin (%)	n.a. n.a. 2018A 0.0 n.a. n.a.	n.a. n.a. 2019A 0.0 n.a. n.a.	n.a. n.a. 2020F 0.0 n.a. n.a.	n.a. n.a. 2021F 0.0 n.a. n.a.	n.a. n.a. 2022F 0.0 n.a. n.a.
Investments Goodwill Other intangible assets Fixed assets Other assets Total assets	0.0 0.0 9.9 0.0 0.0 15.2 0.0 1.1	0.0 0.0 3.0 0.0 0.0 85.5 0.0 2.3	0.0 0.0 3.0 0.0 69.8 0.0 2.1	0.0 0.0 3.0 0.0 0.0 24.5 0.0 6.0	0.0 0.0 3.0 0.0 0.0 35.3 0.0 6.0	Pre-goodwill EPS growth Normalised EPS growth Operating performance Asset turnover (%) EBITDA margin (%) EBIT margin (%) Net profit margin (%)	n.a. n.a. 2018A 0.0 n.a. n.a. n.a.	n.a. n.a. 2019A 0.0 n.a. n.a. n.a.	n.a. n.a. 2020F 0.0 n.a. n.a. n.a.	n.a. n.a. 2021F 0.0 n.a. n.a. n.a.	n.a. n.a. 2022F 0.0 n.a. n.a. n.a.
Investments Goodwill Other intangible assets Fixed assets Other assets Total assets Short-term borrowings Trade payables Long-term borrowings	0.0 0.0 9.9 0.0 0.0 15.2 0.0 1.1 0.0	0.0 0.0 3.0 0.0 85.5 0.0 2.3 0.0	0.0 0.0 3.0 0.0 69.8 0.0 2.1 0.0	0.0 0.0 3.0 0.0 24.5 0.0 6.0 0.0	0.0 0.0 3.0 0.0 35.3 0.0 6.0 0.0	Pre-goodwill EPS growth Normalised EPS growth Operating performance Asset turnover (%) EBITDA margin (%) EBIT margin (%) Net profit margin (%) Return on net assets (%)	n.a. n.a. 2018A 0.0 n.a. n.a. n.a. -45.7	n.a. n.a. 2019A 0.0 n.a. n.a. n.a. -19.2	n.a. n.a. 2020F 0.0 n.a. n.a. n.a. -25.4	n.a. n.a. 2021F 0.0 n.a. n.a. -278.6	n.a. n.a. 2022F 0.0 n.a. n.a. 52.5
Investments Goodwill Other intangible assets Fixed assets Other assets Total assets Short-term borrowings Trade payables Long-term borrowings Provisions	0.0 0.0 9.9 0.0 15.2 0.0 1.1 0.0 0.3	0.0 0.0 3.0 0.0 85.5 0.0 2.3 0.0 0.4	0.0 0.0 3.0 0.0 69.8 0.0 2.1 0.0 0.4	0.0 0.0 3.0 0.0 24.5 0.0 6.0 0.0 0.0	0.0 0.0 3.0 0.0 35.3 0.0 6.0 0.0 0.0	Pre-goodwill EPS growth Normalised EPS growth Operating performance Asset turnover (%) EBITDA margin (%) EBIT margin (%) Net profit margin (%) Return on net assets (%) Net debt (A\$m)	n.a. n.a. 2018A 0.0 n.a. n.a. n.a. -45.7 -2.4	n.a. n.a. 2019A 0.0 n.a. n.a. n.a. -19.2 -72.3	n.a. n.a. 2020F 0.0 n.a. n.a. n.a. -25.4 -59.8	n.a. n.a. 2021F 0.0 n.a. n.a. n.a. -278.6 -14.1	n.a. n.a. 2022F 0.0 n.a. n.a. 52.5 -14.1
Investments Goodwill Other intangible assets Fixed assets Other assets Total assets Short-term borrowings Trade payables Long-term borrowings Provisions Other liabilities	0.0 0.0 9.9 0.0 15.2 0.0 1.1 0.0 0.3 0.3	0.0 0.0 3.0 0.0 85.5 0.0 2.3 0.0 0.4 0.0	0.0 0.0 3.0 0.0 69.8 0.0 2.1 0.0 0.4 0.0	0.0 0.0 3.0 0.0 24.5 0.0 6.0 0.0 0.0 0.4 0.0	0.0 0.0 3.0 0.0 35.3 0.0 6.0 0.0 0.4 0.0	Pre-goodwill EPS growth Normalised EPS growth Operating performance Asset turnover (%) EBITDA margin (%) EBIT margin (%) Net profit margin (%) Return on net assets (%) Net debt (A\$m) Net debt/equity (%)	n.a. n.a. 2018A 0.0 n.a. n.a. n.a. -45.7 -2.4 -18.0	n.a. n.a. 2019A 0.0 n.a. n.a. n.a. -19.2 -72.3 -87.4	n.a. n.a. 2020F 0.0 n.a. n.a. n.a. -25.4 -59.8 -88.8	n.a. n.a. 2021F 0.0 n.a. n.a. -278.6 -14.1 -78.0	n.a. n.a. 2022F 0.0 n.a. n.a. 52.5 -14.1 -48.9
Investments Goodwill Other intangible assets Fixed assets Other assets Total assets Short-term borrowings Trade payables Long-term borrowings Provisions Other liabilities Total liabilities	0.0 0.0 9.9 0.0 15.2 0.0 1.1 0.0 0.3 0.3 1.6	0.0 0.0 3.0 0.0 85.5 0.0 2.3 0.0 0.4 0.0 2.7	0.0 0.0 3.0 0.0 69.8 0.0 2.1 0.0 0.4 0.0 2.5	0.0 0.0 3.0 0.0 24.5 0.0 6.0 0.0 0.4 0.0 6.4	0.0 0.0 3.0 0.0 35.3 0.0 6.0 0.0 0.4 0.0 6.4	Pre-goodwill EPS growth Normalised EPS growth Operating performance Asset turnover (%) EBITDA margin (%) EBIT margin (%) Net profit margin (%) Return on net assets (%) Net debt (A\$m)	n.a. n.a. 2018A 0.0 n.a. n.a. n.a. -45.7 -2.4	n.a. n.a. 2019A 0.0 n.a. n.a. n.a. -19.2 -72.3	n.a. n.a. 2020F 0.0 n.a. n.a. n.a. -25.4 -59.8	n.a. n.a. 2021F 0.0 n.a. n.a. n.a. -278.6 -14.1	n.a. n.a. 2022F 0.0 n.a. n.a. 52.5 -14.1
Investments Goodwill Other intangible assets Fixed assets Other assets Total assets Short-term borrowings Trade payables Long-term borrowings Provisions Other liabilities Total liabilities Share capital	0.0 0.0 9.9 0.0 15.2 0.0 1.1 1.0 0.0 0.3 0.3 1.6 26.6	0.0 0.0 3.0 0.0 85.5 0.0 2.3 0.0 0.4 0.0 2.7 109.5	0.0 0.0 3.0 0.0 69.8 0.0 2.1 0.0 0.4 0.0 2.5 109.5	0.0 0.0 3.0 0.0 24.5 0.0 6.0 0.0 0.4 0.0 6.4 109.5	0.0 0.0 3.0 0.0 35.3 0.0 6.0 0.0 0.4 0.0 6.4 109.5	Pre-goodwill EPS growth Normalised EPS growth Operating performance Asset turnover (%) EBITDA margin (%) EBIT margin (%) Net profit margin (%) Return on net assets (%) Net debt (A\$m) Net debt/equity (%)	n.a. n.a. 2018A 0.0 n.a. n.a. n.a. -45.7 -2.4 -18.0	n.a. n.a. 2019A 0.0 n.a. n.a. n.a. -19.2 -72.3 -87.4	n.a. n.a. 2020F 0.0 n.a. n.a. n.a. -25.4 -59.8 -88.8	n.a. n.a. 2021F 0.0 n.a. n.a. -278.6 -14.1 -78.0	n.a. n.a. 2022F 0.0 n.a. n.a. 52.5 -14.1 -48.9
Investments Goodwill Other intangible assets Fixed assets Other assets Total assets Short-term borrowings Trade payables Long-term borrowings Provisions Other liabilities Total liabilities Share capital Other reserves	0.0 0.0 9.9 0.0 15.2 0.0 1.1 0.0 0.3 0.3 0.3 1.6 26.6 2.0	0.0 0.0 3.0 0.0 85.5 0.0 2.3 0.0 0.4 0.0 0.4 0.0 2.7 109.5 4.1	0.0 0.0 3.0 0.0 69.8 0.0 2.1 0.0 0.4 0.0 2.5 109.5 4.1	0.0 0.0 3.0 0.0 24.5 0.0 6.0 0.0 0.4 0.0 6.4 109.5 4.1	0.0 0.0 3.0 0.0 35.3 0.0 6.0 0.0 0.4 0.0 6.4 109.5 4.1	Pre-goodwill EPS growth Normalised EPS growth Operating performance Asset turnover (%) EBITDA margin (%) EBIT margin (%) Net profit margin (%) Return on net assets (%) Net debt (A\$m) Net debt/equity (%) Net interest/EBIT cover (x)	n.a. n.a. 2018A 0.0 n.a. n.a. -45.7 -2.4 -18.0 n.a.	n.a. n.a. 2019A 0.0 n.a. n.a. -19.2 -72.3 -87.4 389.4	n.a. n.a. 2020F 0.0 n.a. n.a. n.a. -25.4 -59.8 -88.8 65.3	n.a. n.a. 0.0 n.a. n.a. n.a. -278.6 -14.1 -78.0 31.6	n.a. n.a. 0.0 n.a. n.a. 52.5 -14.1 -48.9 -12.7
Investments Goodwill Other intangible assets Fixed assets Other assets Total assets Short-term borrowings Trade payables Long-term borrowings Provisions Other liabilities Total liabilities Share capital Other reserves Retained earnings	0.0 0.0 9.9 0.0 15.2 0.0 1.1 0.0 1.1 0.0 3.0 3 0.3 1.6 26.6 2.0 -15.1	0.0 0.0 3.0 0.0 85.5 0.0 2.3 0.0 2.3 0.0 4.0 0.4 0.4 0.0 2.7 109.5 4.1 -30.7	0.0 0.0 3.0 0.0 69.8 0.0 2.1 0.0 4.0 0.0 2.5 109.5 4.1 -46.2	0.0 0.0 3.0 0.0 24.5 0.0 6.0 0.0 0.0 6.4 109.5 4.1 -95.4	0.0 0.0 3.0 0.0 35.3 0.0 6.0 0.0 0.4 0.0 6.4 109.5 4.1 -84.6	Pre-goodwill EPS growth Normalised EPS growth Operating performance Asset turnover (%) EBITDA margin (%) EBIT margin (%) Net profit margin (%) Return on net assets (%) Net debt (A\$m) Net debt/equity (%) Net interest/EBIT cover (x)	n.a. n.a. 2018A 0.0 n.a. n.a. -45.7 -2.4 -18.0 n.a. 2018A	n.a. n.a. 2019A 0.0 n.a. n.a. n.a. -19.2 -72.3 -87.4 389.4 2019A	n.a. n.a. 2020F 0.0 n.a. n.a. n.a. -25.4 -59.8 -88.8 65.3	n.a. n.a. 2021F 0.0 n.a. n.a. n.a. -278.6 -14.1 -78.0 31.6 2021F	n.a. n.a. 0.0 n.a. n.a. 52.5 -14.1 -48.9 -12.7
Investments Goodwill Other intangible assets Fixed assets Other assets Total assets Short-term borrowings Trade payables Long-term borrowings Provisions Other liabilities Total liabilities Share capital Other reserves Retained earnings Other equity	0.0 0.0 9.9 0.0 15.2 0.0 1.1 0.0 1.1 0.0 3.0.3 1.6 26.6 2.0 -15.1 0.0	0.0 0.0 3.0 0.0 85.5 0.0 2.3 0.0 2.3 0.0 0.4 0.0 2.7 109.5 4.1 -30.7 0.0	0.0 0.0 3.0 0.0 69.8 0.0 2.1 0.0 0.0 0.0 0.0 2.5 109.5 4.1 -46.2 0.0	0.0 0.0 3.0 0.0 24.5 0.0 6.0 0.0 0.0 0.0 0.0 6.4 109.5 4.1 -95.4 0.0	0.0 0.0 3.0 0.0 35.3 0.0 6.0 0.4 0.0 6.4 109.5 4.1 -84.6 0.0	Pre-goodwill EPS growth Normalised EPS growth Operating performance Asset turnover (%) EBITDA margin (%) EBIT margin (%) Net profit margin (%) Return on net assets (%) Net debt (A\$m) Net debt/equity (%) Net interest/EBIT cover (x) Internal liquidity Current ratio (x)	n.a. n.a. 2018A 0.0 n.a. n.a. -45.7 -2.4 -18.0 n.a. 2018A 1.5	n.a. n.a. 2019A 0.0 n.a. n.a. -19.2 -72.3 -87.4 389.4 2019A 26.7	n.a. n.a. 2020F 0.0 n.a. n.a. -25.4 -25.4 -39.8 -88.8 65.3 2020F 23.8	n.a. n.a. 2021F 0.0 n.a. n.a. n.a. -278.6 -14.1 -78.0 31.6 2021F 2.2	n.a. n.a. 0.0 n.a. n.a. 52.5 -14.1 -48.9 -12.7 2022F 2.2
Investments Goodwill Other intangible assets Fixed assets Other assets Total assets Short-term borrowings Trade payables Long-term borrowings Provisions Other liabilities Share capital Other reserves Retained earnings Other equity Total equity	0.0 0.0 9.9 0.0 0.0 15.2 0.0 1.1 0.0 0.3 0.3 1.6 26.6 2.0 -15.1 0.0 13.6	0.0 0.0 3.0 0.0 85.5 0.0 2.3 0.0 2.3 0.0 0.4 0.0 2.7 109.5 4.1 -30.7 0.0 82.8	0.0 0.0 3.0 0.0 69.8 0.0 2.1 0.0 0.4 0.4 0.0 2.5 109.5 4.1 -46.2 0.0 67.3	0.0 0.0 3.0 0.0 24.5 0.0 6.0 0.0 0.0 0.4 109.5 4.1 -95.4 0.0 18.1	0.0 0.0 3.0 0.0 35.3 0.0 6.0 0.0 0.4 0.0 6.4 109.5 4.1 -84.6 0.0 28.9	Pre-goodwill EPS growth Normalised EPS growth Operating performance Asset turnover (%) EBITDA margin (%) EBIT margin (%) Net profit margin (%) Return on net assets (%) Net debt (A\$m) Net debt/equity (%) Net interest/EBIT cover (x) Internal liquidity Current ratio (x) Receivables turnover (x)	n.a. n.a. 2018A 0.0 n.a. n.a. -45.7 -2.4 -18.0 n.a. 2018A 1.5 0.0	n.a. n.a. 2019A 0.0 n.a. n.a. -19.2 -72.3 -87.4 389.4 2019A 26.7 0.0	n.a. n.a. 2020F 0.0 n.a. n.a. n.a. -25.4 -59.8 -88.8 65.3 - 2020F 23.8 0.0	n.a. n.a. 2021F 0.0 n.a. n.a. n.a. -278.6 -14.1 -78.0 31.6 2021F 2.2 0.0	n.a. n.a. 0.0 n.a. n.a. 52.5 -14.1 -48.9 -12.7 2022F 2.2 0.0
Investments Goodwill Other intangible assets Fixed assets Other assets Total assets Short-term borrowings Trade payables Long-term borrowings Provisions Other liabilities Total liabilities Share capital Other reserves Retained earnings Other equity Total equity Minority interest	0.0 0.0 9.9 0.0 15.2 0.0 1.1 0.0 0.3 0.3 1.6 26.6 2.0 0.0 15.1 0.0 13.6 0.0	0.0 0.0 3.0 0.0 85.5 0.0 2.3 0.0 0.4 0.0 2.7 109.5 4.1 -30.7 0.0 82.8 0.0	0.0 0.0 3.0 0.0 69.8 0.0 0.4 0.0 2.1 109.5 4.1 -46.2 0.0 67.3 0.0	0.0 0.0 3.0 0.0 24.5 0.0 0.0 0.0 0.0 0.0 0.4 0.0 6.4 109.5 4.1 -95.4 1.95.4 1.00	0.0 0.0 3.0 0.0 35.3 0.0 6.0 0.0 0.4 109.5 4.1 -84.6 0.0 28.9 0.0	Pre-goodwill EPS growth Normalised EPS growth Operating performance Asset turnover (%) EBITDA margin (%) EBIT margin (%) Net profit margin (%) Return on net assets (%) Net debt (A\$m) Net debt/equity (%) Net interest/EBIT cover (x) Internal liquidity Current ratio (x)	n.a. n.a. 2018A 0.0 n.a. n.a. -45.7 -2.4 -18.0 n.a. 2018A 1.5	n.a. n.a. 2019A 0.0 n.a. n.a. -19.2 -72.3 -87.4 389.4 2019A 26.7	n.a. n.a. 2020F 0.0 n.a. n.a. -25.4 -25.4 -39.8 -88.8 65.3 2020F 23.8	n.a. n.a. 2021F 0.0 n.a. n.a. n.a. -278.6 -14.1 -78.0 31.6 2021F 2.2	n.a. n.a. 0.0 n.a. n.a. 52.5 -14.1 -48.9 -12.7 2022F 2.2
Investments Goodwill Other intangible assets Fixed assets Other assets Total assets Short-term borrowings Trade payables Long-term borrowings Provisions Other liabilities Share capital Other reserves Retained earnings Other equity Total equity	0.0 0.0 9.9 0.0 0.0 15.2 0.0 1.1 0.0 0.3 0.3 1.6 26.6 2.0 -15.1 0.0 13.6	0.0 0.0 3.0 0.0 85.5 0.0 2.3 0.0 2.3 0.0 0.4 0.0 2.7 109.5 4.1 -30.7 0.0 82.8	0.0 0.0 3.0 0.0 69.8 0.0 2.1 0.0 0.4 0.4 0.0 2.5 109.5 4.1 -46.2 0.0 67.3	0.0 0.0 3.0 0.0 24.5 0.0 6.0 0.0 0.0 0.4 109.5 4.1 -95.4 0.0 18.1	0.0 0.0 3.0 0.0 35.3 0.0 6.0 0.0 0.4 0.0 6.4 109.5 4.1 -84.6 0.0 28.9	Pre-goodwill EPS growth Normalised EPS growth Operating performance Asset turnover (%) EBITDA margin (%) EBIT margin (%) Net profit margin (%) Return on net assets (%) Net debt (A\$m) Net debt/equity (%) Net interest/EBIT cover (x) Internal liquidity Current ratio (x) Receivables turnover (x)	n.a. n.a. 2018A 0.0 n.a. n.a. -45.7 -2.4 -18.0 n.a. 2018A 1.5 0.0	n.a. n.a. 2019A 0.0 n.a. n.a. -19.2 -72.3 -87.4 389.4 2019A 26.7 0.0	n.a. n.a. 2020F 0.0 n.a. n.a. n.a. -25.4 -59.8 -88.8 65.3 - 2020F 23.8 0.0	n.a. n.a. 2021F 0.0 n.a. n.a. n.a. -278.6 -14.1 -78.0 31.6 2021F 2.2 0.0	n.a. n.a. 0.0 n.a. n.a. 52.5 -14.1 -48.9 -12.7 2022F 2.2 0.0

3

Rmorgans

Queensland		New South Wale	S	Victoria		Western Australia	
Brisbane	+61 7 3334 4888	Sydney	+61 2 9043 7900	Melbourne	+61 3 9947 4111	West Perth	+61 8 6160 8700
Stockbroking, Corporate Advice, V	Vealth Management	Stockbroking, Corporate Advice, Wealth Management		Stockbroking, Corporate Advice, Wealth Management		Stockbroking, Corporate Advice, Wealth Management	
Brisbane: Edward St	+61 7 3121 5677	Sydney: Grosvenor	+61 2 8215 5000	Brighton	+61 3 9519 3555	Perth	+61 8 6462 1999
Brisbane: Tynan	+61 7 3152 0600	Place		Camberwell	+61 3 9813 2945		
Partners		Sydney: Reynolds	+61 2 9373 4452	Domain	+61 3 9066 3200	South Australia	
Brisbane: North Quay	+61 7 3245 5466	Securities		Geelong	+61 3 5222 5128	Adelaide	+61 8 8464 5000
Bundaberg	+61 7 4153 1050	Sydney: Currency	+61 2 8216 5111	Richmond	+61 3 9916 4000	Exchange Place	+61 8 7325 9200
Cairns	+61 7 4222 0555	House		South Yarra	+61 3 8762 1400	Norwood	+61 8 8461 2800
Caloundra	+61 7 5491 5422	Armidale	+61 2 6770 3300	Southbank	+61 3 9037 9444	Unley	+61 8 8155 4300
Gladstone	+61 7 4972 8000	Ballina	+61 2 6686 4144	Traralgon	+61 3 5176 6055		
Gold Coast	+61 7 5581 5777	Balmain	+61 2 8755 3333	Warrnambool	+61 3 5559 1500		
Holland Park	+61 7 3151 8300	Bowral	+61 2 4851 5555				
lpswich/Springfield	+61 7 3202 3995	Chatswood	+61 2 8116 1700	Australian Capital	Territory		
Kedron	+61 7 3350 9000	Coffs Harbour	+61 2 6651 5700	Canberra	+61 2 6232 4999		
Mackay	+61 7 4957 3033	Gosford	+61 2 4325 0884				
Milton	+61 7 3114 8600	Hurstville	+61 2 8215 5079	Northern Territory			
Newstead	+61 7 3151 4151	Merimbula	+61 2 6495 2869	Darwin	+61 8 8981 9555		
Noosa	+61 7 5449 9511	Mona Vale	+61 2 9998 4200				
Redcliffe	+61 7 3897 3999	Neutral Bay	+61 2 8969 7500	Tasmania			
Rockhampton	+61 7 4922 5855	Newcastle	+61 2 4926 4044	Hobart	+61 3 6236 9000		
Spring Hill	+61 7 3833 9333	Orange	+61 2 6361 9166				
Sunshine Coast	+61 7 5479 2757	Port Macquarie	+61 2 6583 1735				
Toowoomba	+61 7 4639 1277	Scone	+61 2 6544 3144				
Townsville	+61 7 4725 5787	Wollongong	+61 2 4227 3022				

Disclaimer

The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents ("Morgans") do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so. Those acting upon such information without advice do so entirely at their own risk.

This report was prepared as private communication to clients of Morgans and is not intended for public circulation, publication or for use by any third party. The contents of this report may not be reproduced in whole or in part without the prior written consent of Morgans. While this report is based on information from sources which Morgans believes are reliable, its accuracy and completeness cannot be guaranteed. Any opinions expressed reflect Morgans judgement at this date and are subject to change. Morgans is under no obligation to provide revised assessments in the event of changed circumstances. This report does not constitute an offer or invitation to purchase any securities and should not be relied upon in connection with any contract or commitment whatsoever.

Disclosure of interest

Morgans may from time to time hold an interest in any security referred to in this report and may, as principal or agent, sell such interests. Morgans may previously have acted as manager or co-manager of a public offering of any such securities. Morgans affiliates may provide or have provided banking services or corporate finance to the companies referred to in the report. The knowledge of affiliates concerning such services may not be reflected in this report. Morgans advises that it may earn brokerage, commissions, fees or other benefits and advantages, direct or indirect, in connection with the making of a recommendation or a dealing by a client in these securities. Some or all of Morgans Authorised Representatives may be remunerated wholly or partly by way of commission.

Regulatory disclosures

Analyst owns shares in the following mentioned company(ies): N/A

Recommendation structure

For a full explanation of the recommendation structure, refer to our website at morgans.com.au/research disclaimer

Research team

For analyst qualifications and experience, refer to our website at morgans.com.au/research-and-markets/our-research-team

Research coverage policy

For an overview on the stock selection process, refer to our website at morgans.com.au/research-and-markets/company-analysis/Research-Coverage-Policy

Research independence statement

morgans.com.au/Research-Independence-Statement

Stocks under coverage

For a full list of stocks under coverage, refer to our website at morgans.com.au/research-and-markets/company-analysis/ASX100-Companies-under-coverage and morgans.com.au/research-and-markets/company-analysis/EX-100-Companies-under-coverage

morgans.com.au

If you no longer wish to receive Morgans publications please contact your local Morgans branch or write to GPO Box 202 Brisbane QLD 4001 and include your account details

06.09.19